Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;268(4):1210-1221.
doi: 10.1007/s00415-019-09489-5. Epub 2019 Jul 30.

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

Hernan Inojosa  1 , Undine Proschmann  1 , Katja Akgün  1 , Tjalf Ziemssen  2
Affiliations
Review

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

Hernan Inojosa et al. J Neurol. 2021 Apr.

Abstract

Secondary progressive multiple sclerosis (SPMS) is the second most common form of multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will develop SPMS within 15 years and up to two-thirds after 30 years, leading to a progressive decrease of neurological function and limitation of daily activities. Nevertheless, the SPMS diagnosis is often established retrospectively and delayed up to 3 years due to several patient- and clinician-related factors. Definitive clinical diagnostic criteria are lacking and research is currently ongoing to identify imaging and biochemical biomarkers. As new therapies are introduced, early SPMS diagnosis may represent a window of opportunity for intervention. New approaches, endpoints or technologies could help physicians establishing a diagnosis. Here, we review SPMS in relation to its diagnostic and definition challenges and current screening techniques and tools.

Keywords: Definition; Diagnosis; Endpoints; SPMS; Screening.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Khurana V SH, Medin J, Adlard N (2018) Estimated prevalence of diagnosed secondary progressive multiple sclerosis in the Americas and Europe: results from a systematic literature search. In: Paper presented at the poster presented at the American Academy of Neurology Annual Meeting, 21–27 April 2018, Los Angeles, CA, USA.
    1. Multiple Sclerosis International Federation (MSIF). (2013) Atlas of MS 2013. https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf . Accessed 24 Apr 2019
    1. English C, Aloi JJ (2015) New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther 37(4):691–715. https://doi.org/10.1016/j.clinthera.2015.03.001 - DOI - PubMed
    1. Coret F, Perez-Miralles FC, Gascon F et al (2018) Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Mult Scler J Exp Transl Clin 4(2):2055217318783347. https://doi.org/10.1177/2055217318783347 - DOI - PubMed - PMC
    1. Scalfari A, Neuhaus A, Daumer M et al (2014) Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85(1):67–75. https://doi.org/10.1136/jnnp-2012-304333 - DOI - PubMed

MeSH terms

LinkOut - more resources